HK1167432A1 - 於阿茲海默氏症治療方法中的應用 - Google Patents

於阿茲海默氏症治療方法中的應用

Info

Publication number
HK1167432A1
HK1167432A1 HK12108108.8A HK12108108A HK1167432A1 HK 1167432 A1 HK1167432 A1 HK 1167432A1 HK 12108108 A HK12108108 A HK 12108108A HK 1167432 A1 HK1167432 A1 HK 1167432A1
Authority
HK
Hong Kong
Prior art keywords
mgd
csf
treatment
alzheimers disease
polypeptide
Prior art date
Application number
HK12108108.8A
Other languages
English (en)
Inventor
Dirk Behrens
Shannon Marshall
Justin G P Wong
Ge Wu
Aileen Zhou
Cindy Leo
Lewis T Williams
Elizabeth Bosch
Steven Doberstein
Robert Forgan Halenbeck
Kevin Hestir
Min Mei Huang
Ernestine Lee
Haishan Lin
Thomas Linnemann
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of HK1167432A1 publication Critical patent/HK1167432A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
HK12108108.8A 2004-07-22 2012-08-17 於阿茲海默氏症治療方法中的應用 HK1167432A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59056504P 2004-07-22 2004-07-22
US64760405P 2005-01-27 2005-01-27
US66493205P 2005-03-24 2005-03-24
US69901905P 2005-07-14 2005-07-14

Publications (1)

Publication Number Publication Date
HK1167432A1 true HK1167432A1 (zh) 2012-11-30

Family

ID=35448388

Family Applications (2)

Application Number Title Priority Date Filing Date
HK07105690.5A HK1100223A1 (en) 2004-07-22 2007-05-29 Compositions and methods of use for mgd-csf in disease treatment
HK12108108.8A HK1167432A1 (zh) 2004-07-22 2012-08-17 於阿茲海默氏症治療方法中的應用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK07105690.5A HK1100223A1 (en) 2004-07-22 2007-05-29 Compositions and methods of use for mgd-csf in disease treatment

Country Status (8)

Country Link
US (4) US20070264277A1 (zh)
EP (3) EP2479277B1 (zh)
JP (4) JP5435865B2 (zh)
AT (1) ATE540973T1 (zh)
AU (1) AU2005267062C1 (zh)
CA (1) CA2574654C (zh)
HK (2) HK1100223A1 (zh)
WO (1) WO2006012451A2 (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
ATE454455T1 (de) * 2005-01-27 2010-01-15 Five Prime Therapeutics Inc Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
US9060961B2 (en) * 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
CN102083456B (zh) * 2008-03-25 2015-12-02 阿姆拉特斯治疗公司 神经退行性障碍
WO2009137631A2 (en) * 2008-05-07 2009-11-12 Wintherix Llc Methods for identifying compounds that affect expression of cancer-related protein isoforms
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
BR112012013717B1 (pt) 2009-12-10 2020-01-28 Hoffmann La Roche anticorpos de ligação ao csf-1r humano, composição farmacêutica e usos do anticorpo
BR112012022046A2 (pt) 2010-03-05 2017-02-14 F Hoffamann-La Roche Ag ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
MX2012010014A (es) 2010-03-05 2012-09-21 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
SG10201604798SA (en) 2010-05-04 2016-07-28 Five Prime Therapeutics Inc Antibodies that bind csf1r
US20110312506A1 (en) * 2010-06-17 2011-12-22 Dilyx Biotechnologies, LLC Methods and kits for screening protein solubility
CA2853889A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2016073513A1 (en) * 2014-11-03 2016-05-12 Bioincept, Llc Pif binding as a marker for immune dysregulation
RU2718751C2 (ru) 2012-08-31 2020-04-14 Файв Прайм Терапьютикс, Инк. Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r)
US20150329639A1 (en) * 2012-12-12 2015-11-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
JP6534380B2 (ja) 2014-02-25 2019-06-26 コーニング インコーポレイテッド スフェロイド作製用デバイス、スフェロイドの回収方法及び製造方法
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
US11435340B2 (en) 2014-06-09 2022-09-06 Biometry Inc. Low cost test strip and method to measure analyte
WO2015200089A1 (en) 2014-06-23 2015-12-30 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US20160060597A1 (en) * 2014-08-28 2016-03-03 The University Of Maryland, Baltimore Functional myelination of neurons
IL251464B2 (en) 2014-10-29 2023-03-01 Five Prime Therapeutics Inc Combination therapy for cancer
TW201630937A (zh) 2014-12-22 2016-09-01 戊瑞治療有限公司 用於治療ｐｖｎｓ之抗－ｃｓｆ１ｒ抗體
JP6971850B2 (ja) 2015-04-13 2021-11-24 ファイヴ プライム セラピューティクス インク がんの併用療法
CN109715067B (zh) 2016-07-19 2022-05-17 生物统计股份有限公司 使用批量可校准测试条测量分析物的方法和系统
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
WO2018133937A1 (en) * 2017-01-19 2018-07-26 Biontech Ag Engineered cells for inducing tolerance
CN107130009A (zh) * 2017-07-13 2017-09-05 华南理工大学 一种具有免疫活性和抗红细胞溶血活性的新型多肽及其制备方法
JP2020535119A (ja) 2017-09-13 2020-12-03 ファイヴ プライム セラピューティクス インク 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ−１抗体組合せ併用療法
CN109456989B (zh) * 2018-10-31 2022-03-29 陕西慧康生物科技有限责任公司 一种提高毕赤酵母分泌表达的载体的构建方法
CN109593126B (zh) * 2018-11-28 2019-11-22 山西锦波生物医药股份有限公司 多肽、其生产方法和用途
CN109468361B (zh) * 2018-11-29 2021-11-02 电子科技大学 鱼类自然杀伤细胞杀伤细菌感染的单核/巨噬细胞能力的测定方法
CN109596839A (zh) * 2018-12-25 2019-04-09 广州万孚生物技术股份有限公司 人和肽素快速定量检测方法与试剂盒
CA3126741A1 (en) * 2019-01-15 2020-07-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
CN111150841B (zh) * 2019-12-31 2023-08-15 优锐生物医药科技(深圳)有限公司 一种主动免疫调控微粒及其制备方法和应用
CN114113602B (zh) * 2020-08-28 2024-07-02 香港城市大学深圳研究院 免疫球蛋白相关凝血因子x作为急性心肌梗死的生物标志物
WO2023014892A1 (en) * 2021-08-04 2023-02-09 Alpine Biotherapeutics Corporation Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4433092A (en) 1981-03-09 1984-02-21 Champion Spark Plug Company Green ceramic of lead-free glass, conductive carbon, silicone resin and AlPO4, useful, after firing, as an electrical resistor
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
CA1255586A (en) 1984-07-24 1989-06-13 Hendrik M. Geysen Method of determining mimotopes
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co MICROORGANISM PRODUCING TRYPTOPHANE.
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5831036A (en) * 1987-05-04 1998-11-03 Dana Farber Cancer Institute Soluble fragments of human intercellular adhesion molecule-1
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
JPH0525056A (ja) * 1989-07-27 1993-02-02 Max Planck Inst Fuer Saikaiatorii 中枢神経系における神経成長因子合成の調節
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ES2251009T3 (es) 1990-06-28 2006-04-16 Sanofi-Aventis Deutschland Gmbh Proteinas de fusion con partes de inmunoglobulinas, su preparacion y uso.
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
SG47099A1 (en) 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5399349A (en) 1992-02-06 1995-03-21 Paunescu; Calin Treatment of acne
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
JPH09503672A (ja) 1993-10-14 1997-04-15 イミュネックス・コーポレーション Ｆａｓ拮抗剤とその利用
US5643786A (en) * 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6395964B1 (en) 1995-10-24 2002-05-28 The Texas A&M University System Oral immunization with transgenic plants
IL137963A0 (en) 1998-02-19 2001-10-31 Xcyte Teherapies Inc Compositions and methods for regulating lymphocyte activation
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040048249A1 (en) * 2000-01-21 2004-03-11 Tang Y. Tom Novel nucleic acids and secreted polypeptides
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20050176927A1 (en) 2000-12-13 2005-08-11 Griffin Jennifer A. Secreted proteins
AU2002255478A1 (en) * 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
EP1556490A4 (en) * 2002-10-22 2006-04-05 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES

Also Published As

Publication number Publication date
US8178109B2 (en) 2012-05-15
EP1778842A2 (en) 2007-05-02
US20140170145A1 (en) 2014-06-19
JP2016146850A (ja) 2016-08-18
HK1100223A1 (en) 2007-09-14
JP2008507283A (ja) 2008-03-13
EP1778842B1 (en) 2012-01-11
AU2005267062A1 (en) 2006-02-02
CA2574654C (en) 2014-02-18
AU2005267062B2 (en) 2012-05-17
US20110003384A1 (en) 2011-01-06
WO2006012451A2 (en) 2006-02-02
EP2287310B1 (en) 2015-05-06
EP1778842B8 (en) 2012-03-21
JP2015133970A (ja) 2015-07-27
US8575312B2 (en) 2013-11-05
EP2479277A2 (en) 2012-07-25
EP2287310A1 (en) 2011-02-23
JP5435865B2 (ja) 2014-03-05
US20120258071A1 (en) 2012-10-11
WO2006012451A3 (en) 2006-03-30
JP5815638B2 (ja) 2015-11-17
AU2005267062C1 (en) 2013-01-17
ATE540973T1 (de) 2012-01-15
EP2479277B1 (en) 2015-09-02
US20070264277A1 (en) 2007-11-15
JP2014034577A (ja) 2014-02-24
CA2574654A1 (en) 2006-02-02
EP2479277A3 (en) 2012-08-22

Similar Documents

Publication Publication Date Title
HK1167432A1 (zh) 於阿茲海默氏症治療方法中的應用
DK2864360T3 (en) TARGETED THERAPY
MX2008009493A (es) Peptido novedoso y uso del mismo.
IN2015DN02553A (zh)
JP2012515778A5 (zh)
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
RU2009137017A (ru) Композиции и способы применения ангиопоэтинподобного белка 4
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
RU2432360C2 (ru) Вариант еро, обладающий повышенным сродством связывания с рецептором и сниженным антигенным потенциалом, днк, кодирующая такой вариант еро, рекомбинантный экспрессионный вектор, содержащий такую днк, клетка-хозяин, трансформированная или трансфектированная таким вектором, способ получения такого варианта еро и фармацевтическая композиция, содержащая такой вариант еро
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
JP2006506942A5 (zh)
HK1129128A1 (en) Recombinant human interferon-like proteins
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
RU2007115411A (ru) Пептиды hsp60 и их apl-производные и фармацевтические композиции
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
CA2461443A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
WO2006028561A3 (en) Novel purified fabi polypeptides from fransicella tularensis
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
EP1796707A4 (en) PEPTIDES WITH SPECIFIC SEAT IN HEART VESSELS AND RELATED CONJUGATES AND METHOD
ATE356205T1 (de) Milcherzeugungsassoziiertes immunotropisches rinderprotein (cd14), kodierendes gen und verwendung zur aktivierung von b-zellen
PL363501A1 (en) Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
HK1092162A1 (en) Biologically active peptides comprising isoleucyl-valyl-threonyl- asparaginyl-threonyl-threonine (ivtntt)
WO2001053324A8 (en) Novel haptotactic peptides

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190719